摘要
目的观察重组人生长激素(rhGH)对肝硬化低蛋白血症的治疗效果。方法60例肝硬化失代偿期患者随机分为两组,每组30例,两组均隔日输注人血白蛋白10g,治疗组每天皮下注射rhGH4IU一次,共14天。治疗前,治疗结束时及停药后1月、6月观察临床症状及肝功能、生化指标的变化。结果治疗结束时,治疗组及对照组的临床症状均有改善,血清白蛋白含量分别由27.5±3.6g/L和25.7±4.2g/L升至33.2±6.4g/L和34.1±3.2g/L(P<0.05),肝功能指标明显好转。停药1月后,对照组血清白蛋白含量开始下降,而治疗组在停药6月后血清白蛋白仍能维持较高水平(35.2±2.8g/L)。结论rhGH可以明显提高肝硬化患者血清白蛋白水平,疗效持久,远期疗效有待进一步研究。
Aim To study the effects of recombinant human growth hormone （rhGH） on liver cirrhosis patients with hypoalbuminemia. Methods Sixty patients with liver cirrhosis were allocated into two groups （30 in rhGH group and 30 in control group）. The patients in both groups received similar routine therapy including human albumin infusion, while the patients in rhGH group received rhGH （4 IU qd） coincidently for 14 days. Results At the end of the 14-day therapy, the subjective status of patients improved and the level of albumin increased significantly （27.5 ± 3.6 g/L to 33.2 ± 6.4 g/L in rhGH group and 25.7 ± 4.2 g/L to 34.1 ± 3.2 g/L in control） in both groups. The albumin concentration of the control group was decreased （33.1 ± 3.5 g/L） one month after stopping treatment, while in the rhGH group the effect of rhGH therapy could be found until 6 months later with a albumin level of 35.2 ± 2.8 g/L. Conclusions Growth hormone can increase the level of albumin in liver cirrhosis patients and improve the nutrition condition.
出处
《现代消化及介入诊疗》
2006年第1期12-14,共3页
Modern Interventional Diagnosis and Treatment in Gastroenterology
关键词
肝硬化
低蛋白血症
生长激素
Liver cirrhosis
Hypoalbuminemia
Growth hormone
